Regorafenib is an oral multikinase inhibitor primarily indicated for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. By targeting… Read more


































Regorafenib is an oral multikinase inhibitor primarily indicated for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. By targeting key receptor tyrosine kinases such as VEGFR1-3, TIE2, PDGFR, and c-KIT, it effectively inhibits tumor angiogenesis, stromal signaling, and oncogenic progression. This catalogue provides a comprehensive range of Regorafenib-related compounds, including impurity standards, active metabolites, and stable isotope labelled compounds. These materials are essential for pharmaceutical laboratories performing analytical testing, method validation, and quality control. Impurity profiling relies on these high-quality standards to ensure regulatory compliance and identification of degradation products, while stable isotope labelled standards serve as critical internal standards for accurate quantification in bioanalytical procedures like LC-MS/MS. Utilizing these characterized reference standards allows researchers to maintain high precision and data integrity throughout the drug development and manufacturing lifecycle.